An Unusual Observation in Metastatic Neuroendocrine Neoplasm: Diffuse Pattern Hepatic [68Ga]Ga-DOTATATE Uptake Related to Micro-metastatic Disease and Discordance between Dual-Tracer PET-CT Findings and MIB-1 Labelling Index

Parth Baberwal; Sunita N. Sonavane; Sandip Basu

doi:10.1055/s-0044-1801384

World Journal of Nuclear Medicine, Inhaltsverzeichnis

CC BY 4.0 · World J Nucl Med
DOI: 10.1055/s-0044-1801384

Case Report

An Unusual Observation in Metastatic Neuroendocrine Neoplasm: Diffuse Pattern Hepatic [⁶⁸Ga]Ga-DOTATATE Uptake Related to Micro-metastatic Disease and Discordance between Dual-Tracer PET-CT Findings and MIB-1 Labelling Index

Parth Baberwal

¹Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Mumbai, Maharashtra, India

²Homi Bhabha National Institute, Mumbai, Maharashtra, India

,

Sunita N. Sonavane

¹Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Mumbai, Maharashtra, India

²Homi Bhabha National Institute, Mumbai, Maharashtra, India

,

Sandip Basu

¹Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Mumbai, Maharashtra, India

²Homi Bhabha National Institute, Mumbai, Maharashtra, India

› Institutsangaben

Abstract

Neuroendocrine neoplasms (NENs) are a rare and diverse group of neoplasms that can originate from neuroendocrine cells in any organ. We herein present a patient with Grade II neuroendocrine tumor (NET) of the pancreas with bilobar liver metastasis and a MIB-1 labelling index of 15%, who underwent various systemic and targeted therapies. On follow-up, dual-tracer PET-CT imaging with [⁶⁸Ga]Ga-DOTATATE PET/CT showed new onset skeletal metastases and diffuse pattern SSTR (somatostatin receptor) expression in the left lobe of the liver (Krenning score 3), contrasted by absent uptake on [¹⁸F]FDG. Magnetic resonance imaging of the liver confirmed sub-centimetric left liver lobe lesions, further biopsy of which suggested Grade-III NET exhibiting high Ki-67 (55–60%). Thus, a discordance was observed between Ki-67 and the dual-tracer PET-CT findings, emphasizing the complexity of NEN imaging (with possibility of differentiation even in a relatively high Ki-67) and the importance of using multiple tracers for accurate assessment in guiding evidence-based management strategy.

Keywords

metastasis - NET - DOTATATE - FDG - PET - discordance - de-differentiation - dual-tracer PET

Volltext

Referenzen

References
1 Raphael MJ, Chan DL, Law C, Singh S.. Principles of diagnosis and management of neuroendocrine tumours. CMAJ 2017; 189 (10) e398-e404
2 Sadowski S, Reddy S. The role of imaging in neuroendocrine tumors. J Nucl Med 2023; 64 (01) 12-25
3 Sharma P, Qian Y, He M. et al. Dual-tracer PET/CT in neuroendocrine tumors: applications and implications. Cancer Imaging 2023; 23 (01) 5-15
4 Sultana Q, Kar J, Verma A. et al. A comprehensive review on neuroendocrine neoplasms: presentation, pathophysiology and management. J Clin Med 2023; 12 (15) 5138
5 American Cancer Society. Tumor Grade. Accessed August 2, 2024 at: https://www.cancer.org/treatment/understanding-your-diagnosis/staging.html
6 Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000; 182 (03) 311-322
7 Dowsett M, Nielsen TO, A'Hern R. et al; International Ki-67 in Breast Cancer Working Group. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 2011; 103 (22) 1656-1664
8 Luporsi E, André F, Spyratos F. et al. Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat 2012; 132 (03) 895-915
9 Rothenstein J, Cleary SP, Pond GR. et al. Neuroendocrine tumors of the gastrointestinal tract: a decade of experience at the Princess Margaret Hospital. Am J Clin Oncol 2008; 31 (01) 64-70
10 Silveira F, Basile ML, Kuga FS, Próspero JD, Paes RAP, Bernardi FDC. Neuroendocrine tumors: an epidemiological study of 250 cases at a tertiary hospital. Rev Assoc Med Bras (1002) 2007; 63 (10) 856-861
11 Cives M, Strosberg JR. Gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin 2018; 68 (06) 471-487
12 Riihimäki M, Hemminki A, Sundquist K, Sundquist J, Hemminki K. The epidemiology of metastases in neuroendocrine tumors. Int J Cancer 2016; 139 (12) 2679-2686
13 Fazio N, Di Meglio G, Lorizzo K, de Brand F. Miliary hepatic metastases from neuroendocrine carcinoma. Dig Surg 2008; 25 (05) 330
14 D'Souza JC, O'Brien SR, Yang Z, El Jack AK, Pantel AR. Widespread micronodular hepatic metastases of neuroendocrine tumor detected by [⁶⁸Ga]DOTATATE PET/CT. Radiol Case Rep 2022; 18 (02) 481-485
15 Poiană C, Neamţu MC, Avramescu ET. et al. The dedifferentiation of neuroendocrine tumor metastases: myth or reality?. Rom J Morphol Embryol 2013; 54 (01) 201-203
16 Adams S, Baum R, Rink T, Schumm-Dräger PM, Usadel KH, Hör G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 1998; 25 (01) 79-83